Program
Donepezil
Also written as “Donepezil Hydrochloride”, “E2020” and “Donepezil TDS”.
Its studies are mostly in Alzheimer Disease · Down Syndrome · Lewy Body Disease · Cognitive Dysfunction · Dementia, led by 14 companies.
Drug pageDonepezil: every studyMany companies study it; this page follows only the 79 they lead. All 184 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisaiits history only | 391 open or running | phase 4since Sep 12, 2005 | Nov 9, 2004 | May 6, 2030phase 1 · NCT07768592 |
| Pfizerits history only | 70 open or running | phase 4since Sep 9, 2005 | Sep 8, 2005 | none ahead |
| Coriumits history only | 60 open or running | phase 1since Nov 13, 2016 | Nov 13, 2016 | none ahead |
| Merck | 50 open or running | phase 2since Feb 14, 2014 | Oct 21, 2008 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 40 open or running | phase 1since Jan 3, 2012 | Jan 3, 2012 | none ahead |
| Teva Pharmaceutical Industriesits history only | 40 open or running | phase 1since Dec 14, 2010 | Dec 14, 2010 | none ahead |
| AstraZenecaits history only | 30 open or running | phase 1since Jul 9, 2008 | Jul 9, 2008 | none ahead |
| Icure Pharmaceuticalits history only | 30 open or running | phase 3since Jun 22, 2017 | May 15, 2013 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 2since Jun 30, 2006 | Jun 30, 2006 | none ahead |
| Sun Pharmaceutical Industriesits history only | 20 open or running | phase 1since Jan 11, 2011 | Jan 11, 2011 | none ahead |
| AbbVieits history only | 10 open or running | phase 2since Aug 27, 2015 | Aug 27, 2015 | none ahead |
| Dongkook Pharmaceuticalits history only | 10 open or running | phase 1since Feb 18, 2016 | Feb 18, 2016 | none ahead |
| Teikoku Pharma USAits history only | 10 open or running | phase 2since Jun 5, 2009 | Jun 5, 2009 | none ahead |
| Theranexusits history only | 10 open or running | phase 1since Oct 2, 2018 | Oct 2, 2018 | none ahead |
Also a collaborator on its studies: PT Equilab International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 21, 2008First study: phase 1 study in Alzheimer DiseaseFirst studyNCT00777608 · 106 enrolled
- Aug 12, 2010Phase 1 study in DementiaNCT01181310 · 31 enrolled
- Feb 14, 2014Phase 2 study in Alzheimer DiseaseNCT02064920 · 36 enrolled
- Mar 11, 2020Phase 1 study in Alzheimer DiseaseNCT04308304 · 27 enrolled · United States
- Jan 26, 2021Phase 1 study in Alzheimer DiseaseNCT04730635 · 44 enrolled · United States, Australia
TargetBeta
“Acetylcholinesterase inhibitor”ChEMBL 37, by rule
Other programs on ACHE
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| huperzine Arule | wanbangde-pharmaceutical-group-co-ltd | phase 4 | 7 |
| benzgalantamine gluconaterule | alpha-cognition-inc | phase 4 | 1 |
| Z 338rule | Zeria Pharmaceutical | phase 3 | 12 |
Studies
All 5 Merck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04730635Alzheimer Disease · United States, Australia | 1 | Completed | Jan 20, 2023 | 44 |
| NCT04308304Alzheimer Disease · United States | 1 | Completed | May 18, 2022 | 27 |
| NCT02064920Alzheimer Disease | 2 | Completed | Jul 13, 2016 | 36 |
| NCT01181310Dementia | 1 | Completed | Oct 2007 | 31 |
| NCT00777608Alzheimer Disease | 1 | Completed | Oct 2009 | 106 |
How it is read
Names in the registry
- “Donepezil”, 26 entries
- “Donepezil Hydrochloride”, 14 entries
- “E2020”, 7 entries
- “Donepezil TDS”, 5 entries
- “Donepezil hydrochloride”, 5 entries
Conditions, from the studies’ own filings
- Alzheimer Disease, 38 studies
- Down Syndrome, 5 studies
- Lewy Body Disease, 4 studies
- Cognitive Dysfunction, 3 studies
- Dementia, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.